Female Health Company (The) (NASDAQ: VERU) is one of 116 publicly-traded companies in the “Pharmaceuticals” industry, but how does it contrast to its rivals? We will compare Female Health Company (The) to related companies based on the strength of its dividends, institutional ownership, valuation, profitability, risk, analyst recommendations and earnings.

Valuation and Earnings

This table compares Female Health Company (The) and its rivals top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue EBITDA Price/Earnings Ratio
Female Health Company (The) N/A N/A -7.08
Female Health Company (The) Competitors $8.20 billion $2.68 billion -0.88

Female Health Company (The)’s rivals have higher revenue and earnings than Female Health Company (The). Female Health Company (The) is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Female Health Company (The) and its rivals, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Female Health Company (The) 0 0 2 0 3.00
Female Health Company (The) Competitors 837 3752 6776 185 2.55

Female Health Company (The) currently has a consensus price target of $5.00, suggesting a potential upside of 271.75%. As a group, “Pharmaceuticals” companies have a potential upside of 27.80%. Given Female Health Company (The)’s stronger consensus rating and higher possible upside, research analysts plainly believe Female Health Company (The) is more favorable than its rivals.

Profitability

This table compares Female Health Company (The) and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Female Health Company (The) -42.02% -16.78% -10.64%
Female Health Company (The) Competitors -2,859.64% -67.98% -9.26%

Insider & Institutional Ownership

5.0% of Female Health Company (The) shares are owned by institutional investors. Comparatively, 43.7% of shares of all “Pharmaceuticals” companies are owned by institutional investors. 10.9% of Female Health Company (The) shares are owned by insiders. Comparatively, 11.8% of shares of all “Pharmaceuticals” companies are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Volatility and Risk

Female Health Company (The) has a beta of 1.42, indicating that its share price is 42% more volatile than the S&P 500. Comparatively, Female Health Company (The)’s rivals have a beta of 0.90, indicating that their average share price is 10% less volatile than the S&P 500.

Summary

Female Health Company (The) beats its rivals on 6 of the 11 factors compared.

Female Health Company (The) Company Profile

Veru Inc., formerly The Female Health Company, is a therapeutics company focused on developing and commercializing pharmaceuticals and devices in men’s and women’s health and oncology. The Company is engaged in the development, manufacture and marketing of consumer healthcare products. The Company has three divisions: Pharmaceutical and Devices, Consumer Health Products and Public Sector. For men, product and product candidates are in the areas of benign prostatic hyperplasia, male infertility, amelioration of side effects of hormonal prostate cancer therapies, prostate cancer, gout and sexual dysfunction. Women’s Health has product candidates for female sexual health, and advanced breast and ovarian cancers. It manufactures, markets and sells the FC2 Female Condom. FC2 provides dual protection against unintended pregnancy and sexually transmitted infections (STIs), including human immunodeficiency virus/acquired immune deficiency syndrome (HIV/AIDS).

Receive News & Ratings for Female Health Company (The) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Female Health Company (The) and related companies with MarketBeat.com's FREE daily email newsletter.